v3.24.1.1.u2
SOFTWARE DEVELOPMENT COSTS AND LICENSES
 12 Months Ended
Mar. 31, 2024
SOFTWARE DEVELOPMENT COSTS AND LICENSES  
SOFTWARE DEVELOPMENT COSTS AND LICENSES SOFTWARE DEVELOPMENT COSTS AND LICENSES
    Details of our capitalized software development costs and licenses are as follows:
 March 31,
 20242023
CurrentNon-currentCurrentNon-current
Software development costs, internally developed$53.4 $1,237.0 $47.4 $882.0 
Software development costs, externally developed6.1 198.5 2.2 169.7 
Licenses28.8 11.0 16.3 20.5 
Software development costs and licenses$88.3 $1,446.5 $65.9 $1,072.2 
    Software development costs and licenses, net of current portion as of March 31, 2024 and 2023 included $1,433.8 and $1,010.2, respectively, related to titles that have not been released.
Amortization and impairment of software development costs and licenses are as follows:
 Fiscal Year Ended March 31,
202420232022
Amortization of software development costs and licenses$207.2 $179.7 $131.1 
Impairment of software development costs and licenses109.9 79.1 70.6 
Portion representing stock-based compensation(24.4)9.5 (48.4)
Amortization and impairment, net of stock-based compensation$292.7 $268.3 $153.3 
    During the fiscal year ended March 31, 2024, $88.2 of the impairment charges relate to our cost reduction program (refer to Note 21 - Business Reorganization), the remaining $21.7 related to (i) a decision not to proceed with further development of certain interactive entertainment software products, and (ii) recognizing unamortized capitalized costs for the development of a title that exceed the anticipated net realizable value of the asset at the time they were impaired.
As a result of government grants earned on qualified production spend to date, our software development costs and licenses were reduced by $108.3 and $108.1 as of March 31, 2024 and 2023, respectively. We had $198.5 and $0.0 current receivable within Prepaid expenses and other, and $109.3 and $256.8 non-current receivable within Other assets on our Consolidated Balance Sheets relating to such government grants as of March 31, 2024 and 2023, respectively. Within our Consolidated Statements of Operations, Cost of revenue, for fiscal years ended March 31, 2024, 2023, and 2022, was reduced by $45.3, $41.2, and $46.8, respectively, and Research and development expense was reduced by $5.9 for the fiscal year ended March 31, 2024, $4.5 for the fiscal year ended March 31, 2023, with no such reduction in the fiscal year ended March 31, 2022